| Bcr-AblT315I突变慢性髓系白血病靶向治疗的研究进展 |
| |
| 引用本文： | 郑燕,李佳莹,杨勇,陈真. Bcr-AblT315I突变慢性髓系白血病靶向治疗的研究进展[J]. 药学研究, 2017, 36(2): 96-98. DOI: 10.13506/j.cnki.jpr.2017.02.010 |
| |
| 作者姓名： | 郑燕 李佳莹 杨勇 陈真 |
| |
| 作者单位： | 1. 中国药科大学药学医学基础实验教学中心,江苏 南京,211198;2. 中国药科大学药物科学研究院,江苏 南京,211198 |
| |
| 摘 要： | 慢性髓细胞白血病(chronic myeloid leukemia,CML)是一种自我更新的造血干细胞恶性增殖肿瘤.第一代酪氨酸激酶抑制剂伊马替尼的问世,为慢性髓细胞白血病患者带来了福音,但随之后来的耐药是一个巨大的挑战,尤其是Bcr-AblT315I突变引发的耐药程度最高.目前已有多种针对T315I突变的靶向治疗药物的研究,包括已上市的Ponatinib等,本文就近年来针对T315I突变的靶向治疗药物做一综述.
|
| 关 键 词： | 慢性髓系白血病 Bcr-AblT315I突变 伊马替尼耐药 靶向治疗 |
Research progress of targeted therapy for chronic myeloid leukemia with Bcr-AblT315I mutation |
| |
| ZHENG Yan,LI Jiaying,YANG Yong and CHEN Zhen. Research progress of targeted therapy for chronic myeloid leukemia with Bcr-AblT315I mutation[J]. Journal of Pharmaceutical Research, 2017, 36(2): 96-98. DOI: 10.13506/j.cnki.jpr.2017.02.010 |
| |
| Authors: | ZHENG Yan LI Jiaying YANG Yong CHEN Zhen |
| |
| Affiliation: | 1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China,1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China,1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China and 1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China |
| |
| Abstract: | |
| |
| Keywords: | Chronic Myeloid Leukemia Bcr-AblT315I mutation Imatinib-resistant Targeted Therapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《药学研究》浏览原始摘要信息 |
|
点击此处可从《药学研究》下载免费的PDF全文 |
|
